Literature DB >> 1989661

Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.

K Snow1, W Judd.   

Abstract

Cell lines resistant to adriamycin and amsacrine were derived from cloned sublines of the human T cell line Jurkat. Most of the lines resemble atypical MDR cells (Danks et al., 1987; Beck et al., 1987). Thus, resistant Jurkat sublines were cross resistant to several topoisomerase II inhibiting drugs but had low or no resistance to other classes of drugs, resistance was not reversed by verapamil, Pgp was not overexpressed, and drug accumulation was unaltered in resistant compared to parental (control) sublines. Other findings were that anthracycline metabolism differed between resistant and parental sublines, and that resistant sublines displayed altered expression of small polypeptides (less than 20K MW) and an 85K MW protein. Drug resistant cells showed resistance to the production of drug induced cytogenetic aberrations, DNA breaks, and protein-DNA complexes. Resistance was not mediated by altered binding of drugs to DNA or by increased repair of DNA damage. Indirect evidence suggests that the resistant cells had an altered drug-DNA-topoisomerase II association. The study highlights the complex relationships between DNA breaks, cytogenetic aberrations, protein-DNA complexes and drug cytotoxicity, and shows that the relationships differ for adriamycin and amsacrine, suggesting some differences in the modes of action and/or resistance for the drugs and cell lines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989661      PMCID: PMC1971666          DOI: 10.1038/bjc.1991.7

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Glutathione transferases from human liver.

Authors:  M Warholm; C Guthenberg; C von Bahr; B Mannervik
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

2.  Glutathione reductase.

Authors:  I Carlberg; B Mannervik
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

3.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

Authors:  T C Rowe; G L Chen; Y H Hsiang; L F Liu
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

4.  Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.

Authors:  Y Pommier; D Kerrigan; R E Schwartz; J A Swack; A McCurdy
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

5.  Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney.

Authors:  G F Seelig; A Meister
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

Review 6.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

7.  Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines.

Authors:  N K Ahmed
Journal:  Eur J Cancer Clin Oncol       Date:  1985-10

8.  Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.

Authors:  D G Streeter; J S Johl; G R Gordon; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

Authors:  W S Dalton; B G Durie; D S Alberts; J H Gerlach; A E Cress
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.

Authors:  S Merry; C A Fetherston; S B Kaye; R I Freshney; J A Plumb
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

View more
  17 in total

1.  Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.

Authors:  Kun-Peng Zhu; Chun-Lin Zhang; Guo-Qi Shen; Zhong-Sheng Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells.

Authors:  Qingliang Meng; Xiaoqi He; Guangwei Xie; Qingzhong Tian; Xiaogang Shu; Jin Li; Yong Xiao
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

4.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.

Authors:  Qun Zhao; Hui Zhang; Yong Li; Jun Liu; Xiaojie Hu; Liqiao Fan
Journal:  J Exp Clin Cancer Res       Date:  2010-08-30

6.  Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.

Authors:  A Haldane; K M Holdaway; G J Finlay; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Authors:  G J Finlay; E Marshall; J H Matthews; K D Paull; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.

Authors:  Shui-er Zheng; Sang Xiong; Feng Lin; Guang-lei Qiao; Tao Feng; Zan Shen; Da-liu Min; Chun-ling Zhang; Yang Yao
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

9.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

10.  Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.

Authors:  Mingrong Cheng; Xiaoyan Gao; Yong Wang; Houxiang Chen; Bing He; Hongzhi Xu; Yingchun Li; Jiang Han; Zhiping Zhang
Journal:  Mar Drugs       Date:  2013-09-17       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.